The purpose of the Animal Models Core facility is to support and centralize certain aspects of the work in each project proposed. It is our belief that prostate cancer biology is best studied in animal model systems that allow experimental monitoring of progression events such as metastasis and androgen-independent progression. This facility brings together expertise in mouse genetics and human tumor xenografs that will allow basic molecular biological questions to be addressed in state-of-the art model systems with direct relevance to the clinical situation. It also offers an opportunity for translational research questions to be addressed immediately in relevant pre-clinical models. The Core consists of six distinct components which will allow biologically based hypotheses to be tested in Suitable animal models or human prostate cancer xenografts.
The Specific Aims of this Core are as follows: 1. To provide SCID mice to the five research projects 2. To propagate four human prostate cancer xenografts: LAPC4, LAPC9, CWR22, and LUCAP on SCID mice for Investigators in the SPORE. 3. To maintain model mice, such as Pten and Cox-2 conditional knock-out, AKT and Myc transgenic mice as well as reporter lines needed for each project. 4. To provide technical assistance for in vivo experiments, such as harvest xenografts, measure PSA level, and inject pro-drugs for pre-clinical trials. 5. To provide expertise/consultation on animal experimentation and surgical techniques required for the proposed studies. 6. To provide expertise/consultation for the generation of new models.
|Nagarajan, Mahesh B; Raman, Steven S; Lo, Pechin et al. (2018) Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. Abdom Radiol (NY) 43:2487-2496|
|Calais, Jeremie; Fendler, Wolfgang P; Eiber, Matthias et al. (2018) Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med 59:434-441|
|Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control 29:581-588|
|Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 122:76-82|
|Jelinek, David; Flores, Aimee; Uebelhoer, Melanie et al. (2018) Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue. J Vis Exp :|
|Lee, John K; Bangayan, Nathanael J; Chai, Timothy et al. (2018) Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A 115:E4473-E4482|
|Mitra, Mithun; Lee, Ha Neul; Coller, Hilary A (2018) Determining Genome-wide Transcript Decay Rates in Proliferating and Quiescent Human Fibroblasts. J Vis Exp :|
|Zou, Yongkang; Qi, Zhi; Guo, Weilong et al. (2018) Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3K?/?/? Inhibitor BAY1082439. Mol Cancer Ther 17:2091-2099|
|Henning, Susanne M; Galet, Colette; Gollapudi, Kiran et al. (2018) Phase II prospective randomized trial of weight loss prior to radical prostatectomy. Prostate Cancer Prostatic Dis 21:212-220|
|Miller, Eric T; Salmasi, Amirali; Reiter, Robert E (2018) Anatomic and Molecular Imaging in Prostate Cancer. Cold Spring Harb Perspect Med 8:|
Showing the most recent 10 out of 339 publications